Pathway-Directed Therapy in Multiple Myeloma
Lukas John(University of Hohenheim), Marc‐Steffen Raab(Heidelberg University), Klaus Podar(Dana-Farber Cancer Institute), Maria Theresa Krauth(Medical University of Vienna)
Cited by 35
Related Papers
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
|Blood|2004|341
Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells
|Journal of Biological Chemistry|2003|144
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
|Nature Communications|2021|141
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
|British Journal of Haematology|2011|77